Optimizing Outcomes for HR+, HER2- Metastatic Breast Cancer

You must have an ACCC account in order to register for this course/webinar/webinar series.

If You DO NOT Have An ACCC Account:

• To start, click the green “Register” button in the upper right corner of this page. You will be directed to “Your Cart.” Click the green “Log In” button near the top of the page.
  • ACCC members: Click “Reset Password” to update your login information. When your password is updated, you will be redirected to the “My Profile” page, where you can view and update your information.
  • OSS at ACCC Members: Please use your state society login credentials.
  • Non-members: Click “Create Account.” Once your password is created, you will be redirected to the "My Profile" page, where you can view and update your information. Click “Change” to add your Areas of Concentration, then save your information.
• Click “eLearning” at the top of your profile page to go back to the ACCC eLearning portal. In the box on the left side of the screen, click on the “Cart” link.
• The green box in the upper right corner of this page will indicate “You are registered!” for this course. Congratulations!

If You Have An ACCC Account:

• Please click the orange “Log In” button on the left side of this screen. You will be taken to the main login page that displays your email and password. Click the “Log in” button.
• You will be automatically redirected back to this course/webinar page, and the green box in the upper right corner will say that “You are registered!” for this course. Congratulations!

PRO TIP: If you save your ACCC password to your computer and remain logged in, you can register for additional webinars and courses in a matter of seconds—with just one click!

For the best registration and viewing experience, please use Chrome, Edge, or Safari web browsers. Internet Explorer Users may experience difficulties accessing the webinar.

Once you complete your registration, you will receive an email from ACCC eLearning, which contains information on how to access this course/webinar . For assistance with registration or if you do not receive an email, please contact registration@accc-cancer.org.

Overview:

Most patients diagnosed with breast cancer have a subtype that is hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-). While this form of breast cancer is generally highly treatable in its earlier stages, some patients will unfortunately develop metastatic disease. However, the treatment landscape for HR+, HER2- metastatic breast cancer has seen significant advancements in recent years, with the introduction of new therapies that improve both quality of life and progression-free survival. These treatment options include endocrine therapies, CDK4/6 inhibitors, and antibody-drug conjugates (ADCs).

As the number of promising treatment options for patients with HR+, HER2- metastatic breast cancer expands, it remains a challenge for community oncology providers to stay abreast of the latest and most effective management strategies for their patients. To address this need, the Association of Cancer Care Centers (ACCC) is developing an educational series of 3 videos to equip community oncology providers with up-to-date education and information on evidence-based practices for managing treatment and care for this population.

Target Audience:

This continuing education activity is intended for physicians, physician assistants, nurses, pharmacists, APPs.

Fees:

This activity is free for all participants.

Activity Type:

Asynchronous online enduring consisting of 3 videos, pre- and post-activity assessments, and an activity evaluation.

Learning Objectives:

At the end of this educational activity, participants should be able to:

• Discuss evidence-based treatment for patients with HR+, HER2– metastatic breast cancer, including treatment selection strategies
• Outline evaluation and management for patients with potential treatment-related adverse events
• Describe practices that can improve quality of life and clinical outcomes in HR+, HER2– metastatic breast cancer 

Accreditation/Designation of Credit:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians' Education Resource®, LLC and the Association of Cancer Care Centers (ACCC). Physicians' Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC (PER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC has approved this application-based activity for 1.50 ACPE CE hours. The Universal Activity Number for this activity is 0661-9999-24-002-H01-P. Eligibility for credits requires engagement with all online activities, completion of pre- and post-activity assessments with a minimum passing score of 70%, and submission of activity evaluation, NABP e-pid# and month/date of birth within 45 days of activity completion. No partial credits are given. This UAN expires October 28. 2027.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing (CBRN), Provider #16669, for 1.50 total Contact Hours. Eligibility for credits requires full attendance; no partial credits are given.

Faculty, Staff, and Planners:

Program Chair: Pavani Chalasani, MD, MPH · Professor of Medicine · George Washington University

Faculty: Allison Butts, PharmD, BCOP · Pharmacist Manager, Oncology · University of Kentucky, Pavani Chalasani, MD, MPH · Professor of Medicine · George Washington University, Claudia Franco, PA-C · Physician Assistant · Inova Schar Cancer Institute

Planners: Allison Butts, PharmD, BCOP · Pharmacist Manager, Oncology · University of Kentucky,Pavani Chalasani, MD, MPH · Professor of Medicine · George Washington University. Claudia Franco, PA-C · Physician Assistant · Inova Schar Cancer Institute, Molly Kisiel, NP · Director, Clinical Content · Association of Cancer Care Centers, Latha Shivakumar, PhD, CHCP · Director, Clinical Education Development · Association of Cancer Care Centers, Victoria Zwicker, MPH · Program Manager, Education Programs · Association of Cancer Care Centers

Disclosures and Conflict of Interest (COI) Mitigation:

The following individuals have no relevant financial relationships with ineligible companies to disclose: Allison Butts, PharmD, BCOP; Claudia Franco, PA-C; Molly Kisiel, NP; Latha Shivakumar, PhD, CHCP; Victoria Zwicker, MPH; the staffs of ACCC and Physicians’ Education Resource®, LLC.

Pavani Chalsani, MD, MPH - Grant/Research Support: Pfizer, Stemline Therapeutics, Vaxiion Therapeutics, Inc., Personalis, Immutep

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.

How to Request Credit:

To complete the online evaluation(s) and receive a certificate of credit or participation, please visit the post-activity evaluation instructional document embedded in the activity.

Off-Label Disclosure and Disclaimer: This CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician, nurse, or pharmacist relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC or ACCC.

Funding:

This activity is supported by an educational grant from AstraZeneca.

Technology Requirements:

For the best registration and viewing experience, please use Chrome, Edge, or Safari web browsers. Internet Explorer Users may experience difficulties accessing the webinar.

Refund Policy:

As the program is free, refunds are not applicable.